Altem Technologies Private Limited, one of the pioneering companies providing 3D printing solutions in India, has partnered with CELLINK, the world’s first bioink company, to accelerate Life-Science research with 3D Bioprinting in the Indian market. With this partnership, Altem intends to establish a strong presence of bioprinting in the field of medical research and life science applications.
CELLINK AB (NASDAQ: CLNK), founded in 2016 by Eric Gatenholm, is a bio-convergence company that produces bio-ink and bioprinters. The company’s products enable researchers to culture cells in 3D, print human tissues and organs for research purposes.
The partnership with Altem enables Cellink to expand its footprint in the Indian market, providing bioprinting knowhow to researchers to conduct in-vitro studies and reduce the product development time of drugs and medicines.
Commenting on the partnership with Cellink, Mr. Sharath Chandra, Co-founding Director, Altem Technologies (P) Ltd, said, “India has much potential in drug and medicine development and requires more specialized technologies to deliver the future services in life science and healthcare. Through this partnership, we invest in making strategic efforts in identifying and nurturing the 3DBioprinting development opportunities for India. The outcome of this partnership will be to engage and respond to future trends of medicine and healthcare with bio convergence solutions”.
Cecilia Edebo, CEO, CELLINK Bioprinting said, “The convergence of robotics-AI-genomics-bioprinting can contribute to improved quality and future of healthcare. Given the larger addressable population and growing demands for precision medicine, there is a pressing need for addressing the healthcare requirements on priority and calls for accelerated research on the future of healthcare. Our Partnership with Altem will contribute in the direction of developing the technology of tomorrow for creating a better quality of life.”
As per the future market Insights (FMI) report, the global 3D Bioprinting market is expected to grow at a CAGR of at least 13% during 2020-2030. More emphasis will be placed on clinical trials as the biotechnology industry matures, requiring even closer collaboration with top-flight research hospitals. The strong existing R&D community base and massive scope of 3D bioprinting in medical services will drive demand for 3D bioprinting, thus reducing the time and cost of bioconvergence R&D, leading to bringing the innovation early.
Altem, together with CELLINK, is pushing the industry forward and helping the adoption of technologies for the future of medicine by democratizing the 3D Bioprinting technology in India. Days are not far ahead in research where bioprinting of various systems of the human body sustaining and growing outside a human body can be a reality.
Altem’ team of specialists with high expertise in Life-sciences and are now working with some of the top research institutes and hospitals in India to bring revolutionary products to healthcare.